01—Abstract
Summary
Summary of the 10-Q filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's first-quarter 2025 Form 10-Q reports total revenues of $1.05 billiona, up from $880.9 million in the prior-year quarter, driven primarily by JAKAFI product revenues of $709.4 million (versus $571.8 million).
Net product revenues were $922.3 millionb and product royalty revenues were $130.6 million. Net income was $158.2 million, or $0.80 per diluted share, compared with $169.5 million, or $0.75 per diluted share, in the first quarter of 2024. The prior-year quarter benefited from a $99.9 million gain on equity investments, while the current quarter recorded a $1.3 million loss on equity investments.
Interest income fell to $22.9 millionc from $46.8 million as cash and marketable securities balances declined. Operating income rose to $205.2 million from $91.9 million. Cash provided by operating activities was $266.1 million.
At March 31, 2025, the company had $2.4 billiond of cash, cash equivalents and marketable securities and no borrowings under its $500.0 million revolving credit facility. Total stockholders' equity was $3.67 billion. Investors should note several risks disclosed in the filing.
The company has accrued approximately $145.4 million relating to incremental Medicaid rebates tied to its CMS line-extension dispute over OPZELURA. A contract dispute with Novartis over JAKAFI royalties is pending, with a trial scheduled for May 2025. Generic challenges to JAKAFI and OPZELURA are also pending, and the filing reports that the Federal Circuit vacated the preliminary injunction against Sun's deuterated ruxolitinib product (Leqselvi) on April 9, 2025.
02—Key points
Key Highlights
- Total revenues were $1,052.9 million, up from $880.9 million, with JAKAFI net revenues of $709.4 million compared with $571.8 million in the prior-year quarter.
- OPZELURA net revenues rose to $118.7 million from $85.7 million, and NIKTIMVO contributed $13.6 million following its commercial launch in the quarter.
- Net income was $158.2 million ($0.80 diluted EPS), down from $169.5 million ($0.75 diluted EPS), mainly because the prior-year period included a $99.9 million gain on equity investments.
- Income from operations more than doubled to $205.2 million from $91.9 million.
- Cash and cash equivalents were $1.94 billion at March 31, 2025, with total cash, equivalents and marketable securities of $2.4 billion and no borrowings under the $500.0 million revolving credit facility.
- The company accrued approximately $145.4 million for potential incremental Medicaid rebates related to its lawsuit against CMS over treating OPZELURA as a line extension of JAKAFI.
- Pending litigation includes a Novartis royalty dispute (trial scheduled for May 2025) and multiple generic patent challenges to JAKAFI and OPZELURA.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Incyte kept $0.15.
- Revenue$1.05B100.0%
- Cost of revenue−$73.2M7.0%
- Gross profit$979.7M93.0%
- Operating costs−$774.5M73.6%
- Operating income$205.2M19.5%
- Interest, other & tax−$47.0M4.5%
- Net income$158.2M15.0%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 29, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $1.05B$880.89M | +19.5% |
| Cost of Revenue | $73.19M$60.96M | +20.1% |
| Gross Profit | $979.71M$819.93M | +19.5% |
| R&D Expenses | $437.28M$429.26M | +1.9% |
| SG&A Expenses | $325.69M$300.26M | +8.5% |
| Operating Expenses | $847.73M$788.99M | +7.4% |
| Operating Income | $205.17M$91.90M | +123.3% |
| Net Income | $158.20M$169.55M | −6.7% |
| EPS (Basic) | $0.82$0.76 | +7.9% |
| EPS (Diluted) | $0.80$0.75 | +6.7% |
| Shares Outstanding (Basic) | 193.71M224.48M | −13.7% |
| Shares Outstanding (Diluted) | 198.20M227.22M | −12.8% |
05—Questions
Frequently Asked Questions
What drove the increase in Incyte's revenue this quarter?
Total revenues rose to $1,052.9 million from $880.9 million. JAKAFI net revenues increased to $709.4 million from $571.8 million, with the filing citing a volume increase of $98.7 million and a price increase of $38.9 million. OPZELURA net revenues grew to $118.7 million from $85.7 million, and NIKTIMVO added $13.6 million after its launch.
Why did net income decline even though revenue grew?
Net income was $158.2 million compared with $169.5 million a year earlier. The prior-year quarter included a $99.9 million gain on equity investments, which was largely absent this quarter, where the company recorded a $1.3 million loss. Interest income also fell to $22.9 million from $46.8 million, and the provision for income taxes rose to $76.0 million from $66.6 million, with the effective tax rate at 32.4% versus 28.2%.
What is the status of the OPZELURA Medicaid rebate issue?
Incyte sued CMS over a regulation it believes wrongly treats OPZELURA as a line extension of JAKAFI for Medicaid rebates. As of March 31, 2025, the company had accrued approximately $145.4 million for the incremental rebates that would be owed if that treatment applies. The impact on OPZELURA gross-to-net deductions for the quarter was approximately 7.3%. If the company prevails, it would reverse the accrual and have a lower future gross-to-net deduction.
How is the company's balance sheet and liquidity position?
At March 31, 2025, total assets were $5.75 billion and total stockholders' equity was $3.67 billion. Cash provided by operating activities was $266.1 million for the quarter. The company had no outstanding borrowings under its $500.0 million revolving credit facility, which matures in June 2027. Management believes operating cash flow and existing resources will be adequate for its capital needs for the foreseeable future.
What legal and competitive risks could affect JAKAFI revenues?
The filing notes pending patent infringement actions against Apotex and Hikma over generic JAKAFI, with ruxolitinib composition of matter patents expiring with pediatric extension in June 2028. A Novartis royalty dispute over U.S. JAKAFI sales is pending, with a trial scheduled for May 2025. Separately, the Federal Circuit vacated the preliminary injunction that had blocked the launch of Sun's Leqselvi, and the underlying patent case remains pending.
06—Continue